About Axonics
Axonics is a Healthcare company based in Irvine (United States) founded in 2013, and was acquired by Boston Scientific in January 2024. It operates as a sacral neuromodulation devices are developed for urinary and bowel control. Axonics has raised $143.47 million across 7 funding rounds from investors including Boston Scientific, SVB and Edmond de Rothschild. Axonics has completed 2 acquisitions, including Bulkamid and Contura. Its chief executive is Raymond W Cohen. Its website axonics.com draws about 92 thousand monthly visits. Its focus areas include Life Sciences, Genitourinary Disorders, Medical Devices and Therapeutics. Its competitors include Amber Therapeutics, NeuSpera Medical, UroMems, Signum Surgical and Averto Medical and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Axonics was founded in 2013 in Irvine, United States, within the medical device sector. Implantable neurostimulators are developed using sacral neuromodulation technology to address urinary and bowel dysfunctions. The system features a compact device with a helical-tined lead to minimize migration, implanted in the sacral area, and supported by a tablet-based programmer for clinical adjustments. Operations focus on innovation in neuromodulation for pelvic health management.
- Headquarters Irvine, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health
- Email••••••••
- Phone•••• ••••
- Website axonics.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Boston Scientific (Jan 2024)
- Total Equity Funding$143.47M (USD)
in 7 rounds
- Latest Funding Round$20M (USD), Debt – Conventional
Apr 2018
- InvestorsBoston Scientific
& 10 more
- Investments & AcquisitionsBulkamid
& 1 more
- Acquired byBoston Scientific
(Jan 2024)
Apps and channels of Axonics
its YouTube channel Axonics has 3.62K subscribers and 30 videos.
Videos from Axonics
The most watched videos on Axonics's YouTube channel, Axonics (3.62K subscribers). Click a video to play it here.
More on Axonics.
Funding Insights of Axonics
Axonics has successfully raised a total of $143.47M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $20 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $143.47M
- Total Rounds 7
- Last Round Debt – Conventional — $20M
- First Round $32.6M
(Mar 2014)
- Investors Count 10
All 7 funding rounds of Axonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $20.1M | Series C | – | Longitude Capital | |
| Apr 2018 | $20M | Debt – Conventional | – | – | |
| Jul 2017 | $20.5M | Series C | – | – | |
| May 2017 | $14.46M | Series C | – | Edmond de Rothschild, Advent Life Sciences | – |
| Dec 2015 | $38.51M | Series B | – | Advent Life Sciences, Alfred Mann Foundation | |
| Apr 2015 | $17.3M | Series B | – | – | – |
| Mar 2014 | $32.6M | Series A | – | Edmond de Rothschild |
11 investors in total: 11 institutional.
Investors in Axonics
Axonics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, SVB and Edmond de Rothschild.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life science sector | – | longitudecapital.com | Menlo Park, United States | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors | 1953 | edmond-de-rothschild.com | Paris, France | |
Early and mid-stage life science focused VC firm investing in the US and Europe | – | adventls.com | London, United Kingdom | |
Venture Capital firm focused on multiple sectors | – | legendcapital.com.cn | Haidian, China | |
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | – | neomed.net | Oslo, Norway | |
huMannity Medtec is focused on innovating medical technology solutions. | – | aemf.org | Valencia, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Axonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Axonics
125 people are tracked at Axonics (27 in leadership, 4 in board & advisors, 94 in team).
| Name | Role | Group |
|---|---|---|
Raymond W Cohen | CEO | Leadership |
Prabodh Mathur | Chief Product Development Officer | Leadership |
Rinda Sama | COO | Leadership |
Karen Noblett | Chief Medical Officer | Leadership |
Guangqiang Jiang | CTO | Leadership |
Erum Shaikh | Director, Clinical Affairs | Leadership |
Mark Altmann | Director, Therapy Support | Leadership |
Sharmila Karnik | Vp, Project Management | Leadership |
Trishna Dave | Vp, Manufacturing Business Operations | Leadership |
Donald Fischer | Director, Value Analysis | Leadership |
Stacey Rizzolo | Area Sales Director | Leadership |
Henry L. | Vice President Of Mechanical Engineering | Leadership |
Tony Cowley | Director Of Product Management | Leadership |
Paul Scard | Director Of Commercial Operations - UK And Nordic Region, And UK Country Manager | Leadership |
Joseph Cantello | Area Director | Leadership |
Ashley Eriksen | Area Director | Leadership |
Michael Gioffredi | Area Director | Leadership |
Andrea Lord | Area Sales Director | Leadership |
Darin Shirakata | Vp, Manufacturing | Leadership |
Caren Frazier | Area Director | Leadership |
105 more people are available in the full profile.
Complete people profiles for Axonics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axonics
Axonics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bulkamid and Contura.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of the bulking agent for women urinary incontinence | bulkamid.com | London, United Kingdom | 2003 | Feb 2021 | •••• | |
Generic drugs and hydrogel products are manufactured by Contura. | contura.com | London, United Kingdom | 2000 | Feb 2021 | $200M |
Complete acquisition details for Axonics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Axonics
7 dated milestones of Axonics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Axonics is founded.
- Funding First funding round of $32.6M.
- Funding Latest funding round, Debt – Conventional, of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Bulkamid.
- Acquisition Acquires Contura.
- Exit Acquired by Boston Scientific.
Competitors of Axonics
Axonics has 9 listed competitors in our database, 8 of them funded. They include Amber Therapeutics, NeuSpera Medical, UroMems, Signum Surgical and Averto Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amber-tx.com | 2021 | London, United Kingdom | $100M | – | Bioelectrical therapies for peripheral nervous system disorders are developed. | |
| neuspera.com | 2014 | Santa Clara, United States | $123.59M | – | Miniaturized injectable neuromodulation devices are developed for chronic diseases. | |
| uromems.com | 2011 | Grenoble, France | $85.73M | – | Developer of active implantable devices for urological incontinence | |
| signumsurgical.com | 2014 | Galway, Ireland | $5.73M | – | Surgically implanted devices for perianal fistula treatment are provided. | |
| avertomed.com | 2016 | Fremont, United States | $33M | 18 | Medical devices for gastrointestinal disease patients are developed. | |
| americanmedicalsystems.com | 1972 | Minnetonka, United States | – | – | Devices for the treatment of pelvic disorders | |
| boomerangmedical.com | 2021 | Mountain View, United States | $35M | – | Bioelectronic devices are developed for autoimmune disease treatment. | |
| exeromedical.com | 2018 | Or Yehuda, Israel | $10M | – | Develoepr of a sensor device for early detection of anastomotic leaks | |
| leveemedical.com | 2021 | Durham, United States | $24.15M | – | Urological devices for post-prostatectomy incontinence are developed by Levee Medical. |
Detailed competitors of Axonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Axonics
The website of Axonics (axonics.com) receives about 91.6K visits a month and ranks #298,361 among all websites worldwide, #10,357 in Health.
- Monthly visits91.6K
▼ 37.4% vs previous month
- Unique visitors96.9K
per month
- Global rank#298,361
among all websites
- Category rank#10,357
Health · Health
- Bounce rate51%
- Pages per visit1.8
- Average visit50 sec
- DevicesDesktop 14% · Mobile 86%
Websites whose visitors overlap most with Axonics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| elitone.com | 100% | 195.3K | #303,930 | View details | |
| uresta.com | 97% | 50.4K | #591,938 | View details | |
| auncurology.com | 94% | – | #1,275,695 | View details | |
myconfidentlife.com | myconfidentlife.com | 93% | – | #1,848,442 | – |
superbetaprostate.com | superbetaprostate.com | 86% | – | #461,168 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Axonics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as Axonics (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – | |
Bioelectrical therapies for peripheral nervous system disorders are developed. | 2021 | London, England, United Kingdom | USD 116.07 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Axonics
Complete news archive for Axonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axonics
Axonics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Axonics is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Raymond W Cohen is the current CEO of Axonics.
Axonics is a funded company, having raised a total of $143.47M across 7 funding rounds to date. The company's 1st funding round was a Series A of $32.6M, raised on Mar 2014.
Axonics was founded in 2013 in Irvine, United States, within the medical device sector. Implantable neurostimulators are developed using sacral neuromodulation technology to address urinary and bowel dysfunctions. The system features a compact device with a helical-tined lead to minimize migration, implanted in the sacral area, and supported by a tablet-based programmer for clinical adjustments. Operations focus on innovation in neuromodulation for pelvic health management.
Axonics's top competitors include NeuSpera Medical, Amber Therapeutics and UroMems.
Axonics has 11 investors. Key investors include Boston Scientific, SVB, Edmond de Rothschild, Longitude Capital, and Gilde Healthcare.
Yes. Axonics was acquired by Boston Scientific in January 2024.